The Filing Desk

Femasys vs Neuraxis

Femasys FEMY · Neuraxis NRXS · Health Care Equipment

Neuraxis reported revenue of $4 million in fiscal 2025, 1.6 times Femasys' $2 million in fiscal 2025. Femasys' revenue grew 40.8% in its latest year, and Neuraxis' grew 32.9%. Femasys had an operating margin of -767.0%, against -219.4% at Neuraxis. Free cash flow was −$19 million at Femasys and −$6 million at Neuraxis.

Side by side

FemasysNeuraxis
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$4M
Revenue growth40.8%32.9%
Revenue growth a year, last 5 years18.1%—
Gross margin62.0%84.2%
Operating margin−767.0%−219.4%
Net margin−812.3%−218.6%
Free cash flow−$19M−$6M
Free cash flow margin−837.9%−181.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count77.6%31.3%
Last close$1.26$4.50
P/E at the last close——
Insider trades, last 12 monthsbought $74,000, sold $0bought $1.4 million, sold $0
Piotroski F-score2 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
FemasysNeuraxis
Operating margin
Percent of revenue
FemasysNeuraxis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
FemasysNeuraxis

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Femasys and Neuraxis pages.